A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

The outcome of patients with refractory leukemia and myelodysplasia is poor, and new therapies are needed. The antiapoptotic proteins of the Bcl-2 family are overexpressed in these malignancies and are potential therapeutic targets. Therefore, we conducted a phase I clinical trial of the small-molec...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Aaron D. Schimmer, Susan O’Brien, Hagop M. Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis J. Giles, Andre C. Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel‐Reid, Mark S. Berger, Jean Viallet, Gautam Borthakur
Formato: Artigo
Idioma:inglés
Publicado: 2008
Acceso en liña:https://doi.org/10.1158/1078-0432.ccr-08-0999
https://clincancerres.aacrjournals.org/content/clincanres/14/24/8295.full.pdf
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!